| 覃星悦 肖海 樊金莲 农媛 张泰鹏.依达拉奉联合重组组织型纤溶酶原激活剂治疗脑梗死的临床研究[J].现代生物医学进展英文版,2016,16(33):6553-6555. |
| 依达拉奉联合重组组织型纤溶酶原激活剂治疗脑梗死的临床研究 |
| Efficacy of Edaravone and Recombinant Tissue-Type Plasminogen Activatoron Patients with Cerebral Infarction |
| |
| DOI： |
| 中文关键词: 依达拉奉 重组组织型纤溶酶原激活剂 脑梗死 炎症因子 |
| 英文关键词: Edaravone rt-PA Cerebral infarction Inflammatory factor |
| 基金项目: |
|
| Hits: 644 |
| Download times: 0 |
| 中文摘要: |
| 目的：探究依达拉奉联合重组组织型纤溶酶原激活剂(rt-PA)对脑梗死(CI)患者的疗效影响。方法：选取于2013 年5 月~2015
年10 月期间我院收治的CI患者88 例，随机分为对照组和观察组各44 例，对照组给予依达拉奉治疗，观察组在对照组的基础上
予以rt-PA 溶栓治疗，观察两组治疗后的美国国立卫生院神经功能缺损评分(NIHSS) 、疗效及血清肿瘤坏死因子-琢（TNF-琢）和白
介素-6（IL-6）、白介素-12（IL-12）水平的变化。结果：两组治疗后NIHSS 评分均较治疗前显著下降，且观察组较对照组下降更加
显著，差异有统计学意义(P＜0.05)；观察组总有效率为77.27%，明显高于对照组的50.00%，差异有统计学意义(P＜0.05)，且两组
患者在治疗过程中均未出现严重的不良反应。两组治疗后血清炎性因子水平均显著降低，差异具有统计学意义(P＜0.05)，且观察
组改善程度均明显优于对照组，差异具有统计学意义(P＜0.05)。结论：依达拉奉联合rt-PA 能显著减轻CI患者的炎症反应，改善
神经功能缺损程度，值得临床推广。 |
| 英文摘要: |
| Objective:To investigate the therapeutic efficacy of edaravone combined with recombinant tissue-type plasminogen
activator(rt-PA) on patients with cerebral infarction(CI).Methods:A total of 88 cases of patients with CI in our hospital during May 2013
to October 2015were randomlydivided into observation group and control group with 44 cases in each group. The control groupwas treated
with edaravone, the observation group was given rt-PA and thrombolytic therapy on the basis of control group. After treatment, the National
Institutes of Health Stroke Scale (NIHSS), curative effect and changes of serum inflammatory factor include TNF-alpha, interleukin 6
(IL-6), interleukin 12 (IL-12) levels were observed in each group.Results:After treatment, NIHSS scores were significantly decreased
compared with before treatment, and the observation group decreased more significantly than the control group, the difference was statistically
significant (P<0.05); The total effective rate of observation group was 77.27%, significantly higher than 50.00%in control group,
the difference was statistically significant (P<0.05), and there were no serious adverse events during treatment. After treatment, seruminflammatory
factor levels were significantly reduced in the two groups, the difference was statistically significant (P<0.05), and the improvement
degree of the observation group was significantly better than the control group, the difference was statistically significant
(P<0.05).Conclusion:Edaravone combined with rt-PA can significantly reduce inflammation in patients with CI, improve the degree of
neural function defect, it is worthy of clinical promotion. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
